SCHEMBL282065

SCHEMBL282065

N[C@@H](Cc1ccc(Oc2ccc(O)cc2I)c(I)c1I)C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 7/20 0.52
MEN1 O00255 6/20 0.52
BLM P54132 3/20 0.52
PPARG P37231 3/20 0.52
NR1I2 O75469 2/20 0.52
AGTR2 P50052 1/20 0.52
PCNA P12004 2/20 0.48
LMNA P02545 6/20 0.47
HSD17B10 Q99714 4/20 0.47
NPSR1 Q6W5P4 3/20 0.47
ALDH1A1 P00352 3/20 0.47
CYP3A4 P08684 3/20 0.47
MAPT P10636 3/20 0.47
ALOX15 P16050 3/20 0.47
ADORA3 P0DMS8 3/20 0.47
KDM4E B2RXH2 2/20 0.47
NFKB1 P19838 2/20 0.47
PMP22 Q01453 2/20 0.47
TSHR P16473 2/20 0.47
HTR1A P08908 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5574192 1.00 KMT2A (0.52) KMT2AMEN1BLMPPARGNR1I2
SCHEMBL230513 1.00 KMT2A (0.52) KMT2AMEN1BLMPPARGNR1I2
SCHEMBL6350388 0.99 KMT2A (0.51) KMT2AMEN1BLMPPARGNR1I2
SCHEMBL16390915 0.88 KMT2A (0.47) KMT2AMEN1BLMPPARGNR1I2
SCHEMBL10495232 0.87 BLM (0.41) KMT2AMEN1BLMPPARGNR1I2
SCHEMBL10537170 0.87 BLM (0.41) KMT2AMEN1BLMPPARGNR1I2
Hydrochloric Acid SCHEMBL10529768 0.86 BLM (0.41) KMT2AMEN1BLMPPARGNR1I2
SCHEMBL836727 0.85 KMT2A (0.61) KMT2AMEN1BLMPPARGNR1I2
SCHEMBL4355962 0.85 KMT2A (0.61) KMT2AMEN1BLMPPARGNR1I2
SCHEMBL10938099 0.85 KMT2A (0.61) KMT2AMEN1BLMPPARGNR1I2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 795 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260002120-A1 METHODS AND COMPOSITIONS FOR SPINAL CORD CELLS CEDARS-SINAI MEDICAL CENTER (US) 2026-01-01 US claimed
US-20250376659-A1 DERIVATION OF SOMATOTROPHS FROM STEM CELLS AND USES THEREOF MEMORIAL SLOAN-KETTERING CANCER CENTER (US) 2025-12-11 US claimed
US-20240374694-A1 METHOD FOR MANUFACTURING A PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF SPINAL CORD INJURY SUPINE THERAPEUTICS CO., LTD. (KR) 2024-11-14 US claimed
CN-118718106-A Tissue engineering skin based on pluripotent stem cells and preparation method thereof 中科合肥技术创新工程院 2024-10-01 CN claimed
CN-115996710-B Pharmaceutical composition comprising L-triiodothyronine (T3) for the treatment of hypoxia and sepsis 联康药业克雷恩特塞提斯制药实验室有限责任公司 2024-06-28 CN claimed
US-20240189224-A1 IMPLANTABLE DEVICES FOR DRUG DELIVERY WITH REDUCED BURST RELEASE FEDSON, INC. (US) 2024-06-13 US claimed
US-20240076620-A1 PRODUCTION OF SKELETAL MUSCLE CELLS AND SKELETAL MUSCLE TISSUE FROM PLURIPOTENT STEM CELLS GEORG-AUGUST-UNIVERSITÄT GÖTTINGEN STIFTUNG ÖFFENTLICHEN RECHTS, UNIVERSITÄTSMEDIZIN (DE) 2024-03-07 US claimed
US-20230372589-A1 INTERPOSITIONAL IMPLANT FOR GROWTH PLATE INJURY UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) 2023-11-23 US claimed
CN-116745402-A Methods and cell structures 莫纳什大学 2023-09-12 CN claimed
CN-116323918-A Mass production of human pluripotent stem cell-derived cardiac stromal cells 乔治-奥古斯特-哥廷根大学公法大学医学基金会 2023-06-23 CN claimed
EP-0466909-B1 THYROID HORMONE FOR CARDIAC TREATMENT BRITISH TECH GROUP USA (US) 1995-06-28 EP claimed
EP-0424954-B1 Pharmaceutical composition for treatment of osteoporosis NIPPON ZOKI PHARMACEUTICAL CO (JP) 1994-04-27 EP claimed
US-5116828-A Estrogen and thyroid hormone NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JP) 1992-05-26 US claimed
US-H1018-H Immunological method for the determination of free substances having hapten properties HENNING BERLIN GMBH CHEMIE- UND PHARMAWERK (DE) 1992-01-07 US claimed
EP-0424954-A1 Pharmaceutical composition for treatment of osteoporosis NIPPON ZOKI PHARMACEUTICAL CO. LTD. (JP) 1991-05-02 EP claimed
US-4521511-A SUBSTITUTED PHENOLS AS ACCELERATOR ENZYME TECHNOLOGY COMPANY (US) 1985-06-04 US claimed
EP-0103784-A2 Catalyzed colorimetric and fluorometric substrates for peroxidase enzyme determinations ENZYME TECHNOLOGY COMPANY (US) 1984-03-28 EP claimed
US-4110076-A IN UNEXTRACTED BLOOD SERUM MALLINCKRODT, INC. (US) 1978-08-29 US claimed
US-4014651-A RADIOACTIVE LABEL ON THYROID HORMONE MALLINCKRODT, INC. (US) 1977-03-29 US claimed
US-3938953-A Process and device for blood examination using substances labelled with radioactive nuclides HOECHST AKTIENGESELLSCHAFT (DT) 1976-02-17 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260002120-A1 METHODS AND COMPOSITIONS FOR SPINAL CORD CELLS POU2F1, KDR, POU2F2 KMT2A 3618/4885MEN1 3973/4885BLM 4762/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.